GlassScriptPhysician profile
Keith V Yabumoto
NPI 1730383522
$7,901.06
in general payments reported to CMS, 2019-2025
22 companies · $869 in 2025
The $869 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,151 · 2020: $1,290 · 2021: $1,191 · 2022: $751 · 2023: $878 · 2024: $772 · 2025: $869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.31 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,731.56 | 2019-2020 | |
| Medtronic, INC. | $1,723.01 | 2021-2025 | Micra, Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $883.46 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $866.84 | 2019-2025 | Emerge Push, Sentinel, Emblem Mri S-Icd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $712.10 | 2019-2025 | Jardiance |
| Abbott Laboratories | $392.01 | 2019-2023 | Cardiomems |
| Pfizer INC. | $390.92 | 2019-2025 | |
| Amgen INC. | $324.25 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $205.90 | 2019-2024 | Xarelto |
| Kestra Medical Technology Services, INC. | $141.91 | 2023 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $118.35 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $73.86 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.84 | 2023 | |
| Amarin Pharma, INC. | $49.12 | 2020 | |
| Bridgebio Pharma, INC. | $44.84 | 2025 | Attruby |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $42.74 | 2025 | Wainua |
| Sk Life Science, INC. | $35.46 | 2024 | |
| Arbor Pharmaceuticals, INC. | $26.89 | 2020 | |
| Lundbeck LLC | $22.60 | 2021 | |
| Merck Sharp & Dohme LLC | $20.00 | 2021 | |
| Lilly USA, LLC | $19.73 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Yabumoto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.